SS Innovations International, Inc. 8K

SS Innovations International, Inc. reported record second-quarter and first-half 2026 revenues driven by SSi Mantra robotic system growth, while remaining loss‑making and advancing toward U.S. and EU regulatory approvals.

On August 13, 2026, SS Innovations International, Inc. announced its unaudited financial results for the quarter and six months ended June 30, 2026, reporting record quarterly revenue of $13.9 million (up 39.4% year over year) and first-half revenue of $25.0 million (up 65.6%), driven primarily by strong growth in SSi Mantra surgical robotic system sales and installations, alongside higher gross profit but increased operating expenses that resulted in a larger net loss. The company highlighted an expanded installed base of 224 SSi Mantra systems across twelve countries with 12,272 cumulative surgeries performed, no long‑term debt, and $13.6 million of cash and cash equivalents as of June 30, 2026. Management commentary emphasized growing domestic and international adoption, ongoing clinical and training initiatives, and progress toward key regulatory milestones, including an expected FDA 510(k) decision by the end of Q1 2027 and a targeted CE mark in the EU by the end of 2026. The release also described several notable telesurgery achievements that set or broke distance records, participation in high‑profile industry conferences, and an industry award win, while noting that the company concurrently filed its Form 10‑Q for the same period with the SEC.

Filing Facts

CIK

1676163

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-088726

Alert Tier

6